Public Employees Retirement System of Ohio Has $2.06 Million Position in Envista Holdings Co. (NYSE:NVST)

Public Employees Retirement System of Ohio reduced its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,926 shares of the company’s stock after selling 3,157 shares during the period. Public Employees Retirement System of Ohio owned 0.06% of Envista worth $2,063,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Lecap Asset Management Ltd. acquired a new stake in Envista during the 4th quarter worth about $281,000. Norges Bank acquired a new stake in Envista during the 4th quarter worth about $38,052,000. Natixis Advisors LLC grew its stake in shares of Envista by 1.8% in the 4th quarter. Natixis Advisors LLC now owns 106,652 shares of the company’s stock valued at $2,057,000 after buying an additional 1,845 shares during the period. Lightrock Netherlands B.V. acquired a new stake in shares of Envista in the 4th quarter valued at about $5,193,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Envista in the 4th quarter valued at about $10,808,000.

Envista Price Performance

Shares of NYSE NVST opened at $18.29 on Monday. Envista Holdings Co. has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The firm’s 50-day simple moving average is $16.66 and its 200 day simple moving average is $18.73. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The stock has a market cap of $3.10 billion, a price-to-earnings ratio of -2.82, a PEG ratio of 1.27 and a beta of 0.97.

Envista (NYSE:NVST) last posted its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. The firm had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $608.17 million. During the same quarter last year, the firm earned $0.26 EPS. The company’s quarterly revenue was down 1.1% compared to the same quarter last year. As a group, research analysts anticipate that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

NVST has been the subject of several research reports. Bank of America reduced their target price on Envista from $26.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Morgan Stanley set a $16.00 target price on Envista in a research note on Tuesday, April 15th. Robert W. Baird upgraded Envista from a “neutral” rating to an “outperform” rating and raised their target price for the company from $21.00 to $23.00 in a research note on Tuesday, May 27th. Baird R W upgraded Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th. Finally, New Street Research set a $19.00 target price on Envista in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.23.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.